Current Report Filing (8-k)
June 04 2018 - 4:18PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
Current
Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): May 29, 2018
Corcept Therapeutics Incorporated
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-50679
|
|
77-0487658
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
Identification Number)
|
149 Commonwealth Drive
Menlo Park, CA 94025
(Address of principal executive offices, with zip code)
(650)
327-3270
(Registrants telephone number, including area code)
Not Applicable
(Former
name or former, address, if changed since last report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR 240.14d2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR 240.13e4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule
12b-2
of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07
|
Submission of Matters to a Vote of Security Holders
|
On May 29, 2018, we held our annual meeting of
stockholders to consider and vote on proposals: 1) to elect seven directors to hold office until our 2019 annual meeting of stockholders and until their successors are elected and qualified, and 2) to ratify the appointment of Ernst & Young
LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.
A total of 115,235,013 shares of Corcept
Therapeutics Incorporated common stock held by stockholders of record at the close of business on April 18, 2018 were entitled to vote at the annual meeting. The total number of shares voted at the annual meeting was 108,841,664. The voting on
the two matters is set forth below:
Proposal 1 Election of Directors. The following directors were elected to serve until our 2019 annual meeting
of stockholders and until their successors are elected and qualified.
|
|
|
|
|
|
|
|
|
|
|
|
|
Director
|
|
For
|
|
|
Withheld
|
|
|
Broker Non-Votes
|
|
James N. Wilson
|
|
|
79,901,234
|
|
|
|
533,210
|
|
|
|
28,407,220
|
|
G. Leonard Baker, Jr.
|
|
|
79,906,775
|
|
|
|
527,669
|
|
|
|
28,407,220
|
|
Joseph K. Belanoff, M.D.
|
|
|
80,036,906
|
|
|
|
397,538
|
|
|
|
28,407,220
|
|
Daniel M. Bradbury
|
|
|
79,687,700
|
|
|
|
746,744
|
|
|
|
28,407,220
|
|
Reneé D. Galá
|
|
|
79,871,055
|
|
|
|
563,389
|
|
|
|
28,407,220
|
|
David L. Mahoney
|
|
|
77,158,123
|
|
|
|
3,276,321
|
|
|
|
28,407,220
|
|
Daniel N. Swisher, Jr.
|
|
|
80,092,227
|
|
|
|
342,217
|
|
|
|
28,407,220
|
|
Proposal 2 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm
for the fiscal year ending December 31, 2018.
|
|
|
|
|
For
|
|
|
107,929,017
|
|
Against
|
|
|
849,787
|
|
Abstain
|
|
|
62,860
|
|
Broker
Non-Votes
|
|
|
N/A
|
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
CORCEPT THERAPEUTICS INCORPORATED
|
|
|
By:
|
|
/s/ G. Charles Robb
|
|
|
Name: G. Charles Robb
|
|
|
Title: Chief Financial Officer and Secretary
|
Date: June 4, 2018
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Apr 2023 to Apr 2024